Thrombin activatable fibrinolysis inhibitor (TAFI): Relationship to hemostatic alteration in patients with β-thalassemia

Pediatric Hematology and Oncology

Volumn 27, Issue 5, 2010, Pages 363-373

  Mokhtar, Galila M ^a   Matter, Randa M ^a   Shawki, H ^a   Abdel Aziz, Manal M ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

splenectomy; TAFI; thalassemia

Indexed keywords

FERRITIN; HEMOGLOBIN; LIVER ENZYME; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADOLESCENT; ARTICLE; BETA THALASSEMIA; BLEEDING; BLOOD CELL COUNT; CHELATION THERAPY; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ELECTROPHORESIS; EPISTAXIS; FEMALE; FERRITIN BLOOD LEVEL; HEMOSTASIS; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRESCHOOL CHILD; PROTHROMBIN TIME; SCHOOL CHILD; SPLENECTOMY; THALASSEMIA MAJOR; THROMBOEMBOLISM; VIRUS HEPATITIS;

ADOLESCENT; BETA-THALASSEMIA; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CLINICAL ENZYME TESTS; EPISTAXIS; FEMALE; FERRITINS; HEMORRHAGE; HEMOSTASIS; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; SEVERITY OF ILLNESS INDEX; SPLENECTOMY;

EID: 77955104922     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880011003739448     Document Type: Article

References (45)

1. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99:36-43.
2. Paolino E, Monetti VC, Granieri E, Boldrini P. Acute cerebrovascular insults in homozygous betathalassemia: a case report. J Neurol. 1983;230:37-41.
3. Wong V, Yu YL, Liang RH, et al. Cerebral thrombosis in β-thalassemia/hemoglobin E disease. Stroke. 1990;21: 812-816.
4. Sonakul D, Pacharee P, Laohapand T, et al. Pulmonary artery obstruction in thalassemia. Southeast J Trop Med Public Health. 1980;11:516-523.
5. Sonakul D, Fucharoen S. Brain pathology in 6 fatal cases of post transfusion hypertension, convulsion and cerebral hemorrhage syndrome. Southeast Asian J Trop Med Public Health. 1992;23(Suppl 2):116-119.
6. Taher A, Abou-Mourad Y, Abchee A, et al. Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication? Hemoglobin. 2002;26:107-112.
7. Michaeli J, Mittelman M, Grisaru D, Rachmilewitz EA. Thromboembolic complications in beta thalassemia major. Acta Haematol. 1992;87:71-74.
8. Eldor A, Durst R, Hy-Am E, et al. A chronic hyper-coagulable state in patients with beta-thalassemia major is already present in childhood. Br J Haematol. 1999;107:739-746.
9. Angchaisuksiri P, Atichartakarn V, Aryurachai K, et al. Hemostatic and thrombotic markers in patients with hemoglobin E/beta-thalassemia disease. Am J Hematol. 2007;82:1001-1004.
10. Visudhiphan S, Ketsa-Ard K, Tumliang S, Piankijagum A. Significance of blood coagulation and platelet profiles in relation to pulmonary thrombosis in beta-thalassemia/Hb E. Southeast Asian J Trop Med Public Health. 1994;25:449-456.
11. Hussain MA, Hutton RA, Pavlidou O, Hoffbrand AV. Platelet function in beta-thalassemia major. J Clin Pathol. 1979;32:429-433.
12. Lee KF. Fatal intra-cranial haemorrhage in 2 cases of beta-thalassemia major. Med J Malaysia. 1995;50:110-113.
13. Naithani R, Chandra J,Narayan S, et al. Thalassemiamajor-on the verge of bleeding or thrombosis? Hematology. 2006;11:57-61.
14. Sharma S, Raina V, Chandra J, et al. Lupus anticoagulant and anticardiolipin antibodies in polytransfused beta-thalassemia major. Hematology. 2006;11:287-290.
15. Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun. 1989;162: 933-939.
16. Eaton DL, Malloy BE, Tsai SP, et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem. 1991;266:21833-21838.
17. Wang W, Hendriks DF, Scharṕe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem. 1994;269:15937-15944.
18. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477-14484.
19. Wang W, Beffa MB, Baizar L, et al. A study of themechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem. 1998;273:27167-27181.
20. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol. 2006;26:2445-2453.
21. Mosnier LO, Von dem Borne PAK, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact pathway of coagulation. Thromb Haemost. 1998;80:829-835.
22. Silveira A, Schatteman K, Goossens F, et al. Plasma procarboxypeptidase U inmen with symptomatic coronary artery disease. Thromb Haemost. 2000;84:364-368.
23. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95:2855-2859.
24. Franco R, Fagundes MG, Meijers JCM, et al. Identification of polymorphisms in the 5-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica. 2001;86:510-517.
25. Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3 region of the TAFI gene: evidence that the plasma TAFI antigen levels are strongly genetically controlled. Blood. 2001;97:2053-2058.
26. Tregouet DA, Aubert H, Henry M, et al. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet. 2001;109:191-197.
27. Mosnier LO, Buijtenhuijs P, Marx PF, et al. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood. 2003;101:4844-4846.
28. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability and enzymatic properties. J Biol Chem. 1998;273:2127-2135.
29. Watanabe R, Wada H, Watanabe Y, et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res. 2001;104:1-6.
30. Sosothikul D, Seksarn P, Pongsewalak S, et al. Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection. Thromb Haemost. 2007;97:627-634.
31. Sonmez M, Aydin K, Durmus A, et al. Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever. J Infect. 2007;55:184-187.
32. Tripatara A, Jetsrisuparb A, Teeratakulpisarn J, Kuaha K. Hemostatic alterations in splenectomized and non splenectomized patients with beta-thalassemia/ hemoglobin E disease. Thromb Res. 2007;120:805-810.
33. Prati D, Maggioni M, Milani S, et al; Cooleycare Cooperative Group. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica. 2004;89:1179-1186.
34. Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol. 2002; 2:3.
35. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassemia major. Br J Haematol. 2000;110:971-977.
36. Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta-thalassemia. Am J Hematol. 2005;80:70-74.
37. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost. 2001;85:667-670.
38. Gresele P, Binetti BM, Branca G, et al. TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival. Thromb Res. 2008;121:763-768.
39. el-Gohary A, Hassan A, Nooman Z, et al. High prevalence of hepatitis C virus among urban and rural population groups in Egypt. Acta Trop. 1995;59:155-161.
40. el-Nanawy AA, el-Azzouni OF, Soliman AT, et al. Prevalence of hepatitis-C antibody seropositivity in healthy Egyptian children and four high risk groups. J Trop Pediatr. 1995;41:341-343.
41. Heylen E, Miljic P, Willemse J, et al. Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. Thromb Res. 2009;124:427-432.
42. Shebl SS, el Sharkawy HM, el Fadaly NH. Hemostatic disorders in non splenectomized and splenectomized thalassemic children. East Mediterr Health J. 1999;5:1171-1177.
43. Nathan DG. Thalassemia: the continued challenge. Ann N Y Acad Sci. 2005;1054:1-10.
44. Opartkiattikul N, Funahara Y, Hijikata-Okunomiya A, Yamaguchi N, Fucharoen S, Talalak P. Detection of PF3 availability in whole blood from volunteers and beta-thalassemia/HbE patients: a promising method for prediction of thrombotic tendency. Southeast Asian J Trop Med Public Health. 1992;23(Suppl 2):52-59.
45. Panigrahi I, Agarwal S. Thromboembolic complications in beta-thalassemia: beyond the horizon. Thromb Res. 2007;120:783-789.